Abstract: OBJECTIVE To study the relationship between hepatitis B virus (HBV) infection in diffuse large B-cell lymphoma(DLBCL) patients and clinical pathological features and prognosis, so as to provide basic theory for clinical treatment. METHODS A total of 160 cases of DLBCL patients were selected from our hospital from Jan. 2005 to Dec. 2010 as lymphoma group, 160 cases other cancer patients during the same period as other tumor group, and 160 cases of healthy people as health group. Positive rates of Hepatitis B surface antigen (HBsAg) were compared among three groups. Clinicalpathological features and prognosis between the lymphoma group HBsAg-positive and negative patients were compared. RESULTS The HBsAg positive rate of lymphoma study group was 22.5% (36/160), which was higher than that of other tumor group 9.38% (15/160) and health group 5.63% (9/160),and the differences were significant (P<0.05),and the difference had no significant difference between other tumor group and healthy group (P>0.05). DLBCL patients was related to clinical stage, liver involvement, spleen involvement, and ECOG score, and the difference was significant (P<0.05). The new-onset liver injury rate, complete remission rate, and five-year survival rate of HBsAg positive patients and negative patients were 29.63%, 33.33%, 64.71% and 6.03%, 53.23%, 81.90%, respectively, and the differences were significant (P<0.05). CONCLUSION HBV infection and DLBCL patients clinical pathological features maybe correlated and will affect the prognosis of patients, DLBCL combined HBsAg positive patients should be strengthened with antiviral therapy and liver function monitoring.